艾曲波帕（Eltrombopag）50mg
1. Composition:
The active ingredient in Eltrombopag is Eltrombopag, with the chemical name N-[(2E)-3-(4-(2-(4-(2-methylphenyl)-1H-imidazol-1-yl)ethoxy)phenyl)prop-2-enoyl)amino]propanamide. Its molecular formula is C20H22N4O4, and its molecular weight is 378.42 g/mol.
2. Pharmacological Effects:
Eltrombopag stimulates platelet production in the bone marrow, increasing platelet counts. It is indicated for:
- Idiopathic Thrombocytopenic Purpura (ITP): Helps to raise platelet levels and reduce the risk of bleeding.
- Chronic Liver Disease-Related Thrombocytopenia: Improves platelet counts in patients and aids in managing complications associated with liver disease.
3. Usage Instructions:
Eltrombopag is typically administered in oral tablet form, with a recommended dosage of 50 mg per day. The specific dosage may be adjusted based on the patient’s platelet count and response. Eltrombopag can be taken with food, but care should be taken to avoid taking it with high-calcium foods (such as dairy products) to prevent affecting drug absorption.
4. Research & Development History:
Eltrombopag was developed by GlaxoSmithKline (GSK) and was first approved by the U.S. Food and Drug Administration (FDA) in 2008 for the treatment of Idiopathic Thrombocytopenic Purpura. Subsequently, Eltrombopag demonstrated its efficacy in increasing platelet counts in multiple clinical trials, leading to an expansion of its indications.
5. Mechanism of Action:
Eltrombopag is an oral small molecule drug that acts on key pathways of platelet production. It is a selective small molecule thrombopoietin (TPO) receptor agonist that binds to TPO receptors, activating the JAK2 signaling pathway, promoting the proliferation and differentiation of megakaryocytes, and thus increasing platelet production.
6. Summary:
Eltrombopag is an effective drug used for the treatment of Idiopathic Thrombocytopenic Purpura and chronic liver disease-related thrombocytopenia. By stimulating platelet production, it significantly increases platelet levels in patients and reduces the risk of bleeding.
